Target Validation Information
TTD ID	T08391
Target Name	Janus kinase 2 (JAK-2)
Type of Target	Successful
Drug Potency against Target	ITF2357	Drug Info	IC50 = 1~10 nM	[3]
	Ruxolitinib	Drug Info	IC50 = 4.5 nM
	Atropisomer 1	Drug Info	IC50 = 270 nM	[1]
	NSC-1771	Drug Info	IC50 = 223 nM	[2]
Action against Disease Model	ITF2357	Drug Info	The clonogenic activity of JAK2V617F mutated cells was inhibited by low concentrations of ITF2357 (IC50 0.001-0.01 mu M)	[3]
References
REF 1	Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41.
REF 2	In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
REF 3	The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia. 2008 Apr;22(4):740-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.